BACK (IMAC Holdings) Tariff Resilience Score: 6/10 (As of Jun. 26, 2026)


What is IMAC Holdings Tariff Resilience Score?

IMAC Holdings BACK Tariff Resilience Score is 6 as of Jun. 26, 2026. The stock has 7 warning signs investors should review. Among 677 Healthcare Providers & Services companies, IMAC Holdings ranks better than 83.46% on this metric.

IMAC Holdings has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

IMAC Holdings has IMAC Holdings has limited exposure to tariffs due to its focus on healthcare services. While equipment imports could be affected, the impact is minimal. The company has some flexibility in sourcing and pricing, reducing vulnerability to trade tensions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes IMAC Holdings might have Average Resilient.

IMAC Holdings  (OTCPK:BACK) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

IMAC Holdings Tariff Resilience Score Related Terms

BACK vs FCHS, NHLG, NIVF: Tariff Resilience Score Comparison

For the Medical Care Facilities subindustry, IMAC Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IMAC Holdings Tariff Resilience Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, IMAC Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where IMAC Holdings's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
IMAC Holdings (BACK) has a Tariff Resilience Score of 6 as of Jun. 26, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, IMAC Holdings ranks #112 out of 677 companies in the Healthcare Providers & Services industry, placing it in the top 16.5%.
Is IMAC Holdings' Tariff Resilience Score too high?
IMAC Holdings' current Tariff Resilience Score is 6. Based on the distribution chart, IMAC Holdings ranks #112 out of 677 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does IMAC Holdings' Tariff Resilience Score compare to FCHS and NHLG?
According to the Healthcare Providers & Services industry distribution chart, IMAC Holdings ranks #112 out of 677 companies for Tariff Resilience Score. This places IMAC Holdings in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Healthcare Providers & Services company?
A good Tariff Resilience Score depends on the Healthcare Providers & Services industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. IMAC Holdings's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMAC Holdings stock overvalued right now?
IMAC Holdings (BACK) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For IMAC Holdings (BACK), the current Tariff Resilience Score is 6 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IMAC Holdings Business Description

Address 3401 Mallory Lane, Suite 100, Franklin, TN, USA, 37067
IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.